Introduce your patients to the only medical probiotic

Pendulum has developed a unique medical probiotic that helps in the management of Type 2 diabetes.

Containing Akkermansia muciniphila and a blend of four other high-potency bacteria strains, Pendulum Glucose Control was shown in a clinical trial to help manage Type 2 diabetes in people who were also taking metformin.

A medical food is a substance consumed internally or by mouth - either eaten or swallowed, under the supervision of a physician which is intended for the specific dietary management of a disease or condition. This sets Pendulum Glucose Control apart from both drugs and standard probiotics.

A1C Reduction 1

-0.6%

Post Prandial Glucose spike reduction 2

-32.5%

Our clinical trial.

We conducted a double-blind, placebo-controlled nutrition study that demonstrated:

• Pendulum Glucose Control’s safety

• Pendulum Glucose Control statistically and clinically significant impact on A1C and post-meal blood-glucose spikes

Clinical trial included participants taking metformin, compared to placebo. 1. Regarding the decreased A1C level, there was a reduction in mean A1C compared to placebo. 2. Regarding the Post Prandial Glucose Spike Reduction, the observed reduction in glucose AUC would be expected to increase the time spent within the healthy glucose range (TIR70-180) during continuous glucose monitoring. Increases in TIR70-180 strongly correlate to both reductions in A1C and reduction in risk for complications in T2D patients (see details here).

Read now

Mechanism of Action

Pendulum Glucose Control is a patented formulation of five anaerobic probiotics strains, as well as the prebiotic inulin—which provides the initial food source for the 5 probiotics.

This unique synbiotic helps restore the body’s natural capabilities to produce butyrate, which helps meet the unique dietary needs of people with Type 2 diabetes.

Butyrate is the primary energy source for colonocytes. Butyrate binds to specific receptors within the gut mucosa and stimulates the release of glucagon-like peptide-1 (GLP-1), which is an incretin hormone. Glucagon-like peptide-1 is deficient in people with impared glucose tolerance and Type 2 diabetes, which contributes to hyperglycemia.

In people who are not living with Type 2 diabetes, GLP-1

Promotes satiety and reduces appetite
Enhances insulin secretion in the beta cells
Reduces glucose output from the liver
Helps regulate gastric emptying

Pendulum Glucose Control works by:

Relying on the body’s ability to produce short-chain fatty acids—including butyrate
Restoring the mucin lining of the gut

Our studies

Medical Food Assessment Using a Smartphone App with Continuous Glucose Monitoring Sensors: Proof-of-Concept Study

Read Study

Improvements to Postprandial Glucose Control in Subjects with Type 2 Diabetes (T2D)

Read Study

Review: Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease

Read Study

Pendulum Glucose Control is more than a probiotic, it’s a medical food

Medical foods are a special product category distinct from pharmaceuticals, conventional foods, and supplements.

As defined by Congress in the Orphan Drug Act, the term medical food, is: A food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements based on recognized scientific principles, are established by medical evaluation.

In other words, Pendulum Glucose Control is uniquely designed to help with the dietary management of Type 2 diabetes.

Our strains deserve a spotlight

The powerful ingredients behind Pendulum Glucose Control’s probiotic blend.

Akkermansia muciniphila

The gut-lining builder

A highly targeted strain that can only be found in Pendulum Glucose Control & Akkermansia products. People with Type 2 diabetes are shown to be deficient in Akkermansia, which can be associated with healthy weight management.

Clostridium butyricum

The digestive health & butyrate-producer

Naturally found in the human GI tract, this strain is named for its ability to produce high amounts of the short-chain fatty acid butyrate. It has been associated with digestion support and immune health.

Clostridium beijerinckii

The other butyrate producer

This novel strain produces the short-chain fatty acid butyrate, which helps the body process sugar.

Anaerobutyricum hallii

Another butyrate producer

Have we mentioned the importance of butyrate? This is another strain known to produce butyrate, helping the body process sugar and heal the lining of the gut.

Bifidobacterium infantis

The digestive health booster

Breaks down a range of foods and produces the intermediate molecules that are used by the three butyrate-producing strains above. This strain helps maintain a healthy GI tract and helps alleviate IBS symptoms.

Chicory inulin

The probiotic power source for blood sugar

A soluble fiber that can travel to the lower gut and stimulate the growth of the probiotics above. Studies have shown that inulin helps lower fasting blood sugar, reduces fasting insulin, and improves good cholesterol in people with type 2 diabetes.

See our pipeline

Improvements to Postprandial Glucose Control in Subjects with Type 2 Diabetes (T2DM)
Medical Food Assessment Using a Smartphone App With Continuous Glucose
Monitoring Sensors: Proof-Of-Concepts Study
Review: Butyrate-Producing Human Gut Symbiant, Clostridium Butyricum, And It’s Role in Health and Disease
Increased circulating butyrate and ursodeoxycholate during probiotic intervention in humans with type 2 diabetes

Prediabetes Observational Study, Double-Blind, Placebo-controlled

Mayo Clinic Partnership Customer Registry

Exploratory Customer CGM Study

Safety and Metabolic Effects in Type 2 Diabetes - Part II

Metabolomics in Type 2 Diabetes

Factsheets for you and your patients

For Health Care Professionals

Glucose Control Fact Sheet

Top HCP Q&A

HCP Overview Sheet

Pendulum Partners Information

For Patients and Clients

Patient Fact Sheet

Science starts with collaboration

From Ph.D.s to MDs to RDs, we’re surrounded by smarts.

We’ve partnered with top doctors, researchers, and scientists from pretty impressive institutions—like Stanford, Johns Hopkins, UCLA, Mayo Clinic, and the American Diabetes Association.

Our medical research team is led by Chief Medical Officer Orville Kolterman, MD. Dr. Kolterman is a diabetes expert and previous Chief Medical Officer at Amylin Pharmaceuticals, where he brought four diabetes drugs from early-stage development through trials to market.

Together with Dr. Kolterman, we work with leading diabetes professionals to ensure our products deliver results and meet the highest standards of efficacy and safety.